Speakers

Louis Boon, PhD

JJP Biologics

Chief Scientific Officer and Board Member

Louis is the CSO and Management Board Member of JJP Biologics, an innovative new Polish Company backed by the Starak family. JJP Biologics develops the next generation of novel therapeutic biologics around personalized medicine and companion diagnostics. Louis was the founder of various companies focused on the generation and development of therapeutic monoclonal antibodies, primarily in the field of cancer and inflammation. Louis is an author of over 390 publications in international scientific journals in the field of medical biotechnology and an inventor at more than 20 patent applications.

Biomarker, FIRST! IgA and its Receptor CD89

Autoantigen-specific IgA autoantibodies closely correlate with severe symptoms in a subgroup of patients in multiple autoimmune and fibrotic diseases. This is due to CD89-mediated activation of myeloid cells, leading to inflammation and severe tissue damage. High serum levels of autoantigen-specific IgA antibodies serve as companion diagnostic to stratify patients for personalized treatment with JJP-1212.

Read the interview with Louis Boon: The smart goose in drug development

JJP Biologics

Generating new and novel biologics

JJP Biologics is an innovative Polish biotechnology company developing novel therapeutic biologics around personalized medicine and companion diagnostics. JJP Biologics lead programs are JJP-1212 an antagonist anti-CD89 antibody and JJP-1008 with application in immune-oncology. They are part of the growing Polish biotechnology sector, led by some of the biggest names in the industry and backed by the Starak family.

Research and innovation is the bedrock of their business. JJP Biologics advances leading-edge science through a dynamic and collaborative approach. This enables them to find better solutions for treating the world’s most challenging diseases. They focus on discovering, developing and delivering drugs in therapeutic areas where they have proven expertise—and can make an impact. This is mainly focused around immunology, inflammation and oncology.

Visit the website of JJP Biologics